Day 3 - Sunday, 11 April, 2010

The Lancet Oncology/Clinical Oncological Society of Australia Plenary Session (Nusantara 1, Level 2)
Moderators:Bruce MANN (Australia), David COLLINGRIDGE (UK)

0830 – 0835

Introduction
Bruce MANN (Australia)

0835 – 0845

Can we improve informed consent? An international randomised controlled trial of consultation skills training
Phyllis BUTOW (Australia)

0845 – 0850

0850 – 0900

The prognostic importance of p16INK4A and HPV in patients with oropharyngeal cancer treated with concurrent chemoradiation on TROG 02.02 phase III trial.
Danny RISCHIN (Australia)

0900 – 0905

0905 – 0915

Interim analysis of the APML4 trial incorporating all-trans retinoic acid (ATRA), idarubicin, and intravenous arsenic trioxide (ATO) as initial therapy in acute promyelocytic leukaemia (APL): An Australasian Leukaemia and Lymphoma Group (ALLG) study.
Harry ILAND (Australia)

0915 – 0920

0920 – 0930

GOFURTGO trial (GFG) – an AGITG multicentre phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC).
David GOLDSTEIN (Australia)

0930 – 0935

0935 – 0945

Early results of a randomised trial comparing surgery alone with surgery plus post-operative radiation therapy following resection of melanoma involving regional lymph nodes – results of the TROG 02.01/ANZMTG 01.02 Intergroup Trial.
Bryan BURMEISTER (Australia)

0945 – 0950

0950 – 1005

Q&A / Discussions

1005 – 1015

Editor's Choice Poster Awards prize giving ceremony

1015 – 1045

Tea Break
Exhibition & Networking

Gastrointestinal Cancer Suite Nusantara 3, Level 2	Genitourinary Cancer Suite Nusantara 2, Level 2	Thoracic Cancer Suite Jakarta B, Level 2	Women's Health Suite Nusantara 1, Level 2	Supportive Oncology Suite Jakarta A, Level 2
GI Symposium 3 Hepatocellular Carcinoma Moderators: Thomas YAU (Hong Kong), Laurentius MA LESMANA (Indonesia)	GU Symposium 3 Prostate Cancer II Moderator: James DENHAM (Australia)	TC Symposium 3 Recent Advances in Lung Cancer Research Moderators: Noorwati SUTANDYO (Indonesia), Elisna SYAHRUDDIN (Indonesia)	WH Symposium 3 Updates in the Treatment of Gynaecologic Cancers Moderators: Efren DOMINGO (Philippines), Laila NURANNA (Indonesia)	SP Symposium 3 Transiting from Curative to Palliative: Clinical Decision Making Moderators: Ednin HAMZAH (Malaysia), Zubairi DJOERBAN (Indonesia)

1045 – 1115

Targeted therapy in HCC CHENG Ann-Lii (Taiwan)

Optimal treatment of hormone-sensitive prostate cancer: have we max'ed out? Michael CARDUCCI (USA)

EGFR mutation in never smoker: Impact of second-hand smoking Byoung Chul CHO (South Korea)

Updates on management of endometrial cancer Hextan NGAN (Hong Kong)

Clinical decision making in advanced cancer Ghauri AGGARWAL (Australia)

1115 – 1145

Picking the right patients for transplant vs resection CHEOW Peng Chung (Singapore)

Hormone-resistant prostate cancer: have we made any progress since docetaxel? Michael CARDUCCI (USA)

Novel targets and phase I/II agents in NSCLC LIN Chia-Chi (Taiwan)

Updates on chemotherapy treatment of ovarian cancer Sarikapan WILAILAK (Thailand)

Panel discussion: Communicating options & eliciting patient preferences Ghauri AGGARWAL (Australia) Cynthia GOH (Singapore) MR RAJAGOPAL (India)

1145 – 1200

Q&A

Q&A

Q&A

Q&A

Q&A

1205 – 1310

Bayer Satellite Lunch Symposium (Nusantara 3, Level 2)
The era of systemic therapy for the treatment of hepatocellular carcinoma

GI Symposium 4 Colorectal Cancer Moderators: Cornelis JH VAN DE VELDE (Netherlands), Aru W SUDOYO (Indonesia)

GU Symposium 4 Renal Cell Carcinoma Moderator: Ronald BUKOWSKI (USA)

TC Symposium 4 Recent Advances in the Treatment of Lung Cancer Moderator: CHO Byoung Chul (South Korea)

WH Symposium 4 Cervical Cancer Prevention Moderators: Sarikapan WILAILAK (Thailand), Farid AZI (Indonesia)

SP Symposium 4 Transiting from Curative to Palliative: Talking about DNR Moderators: M.R. RAJAGOPAL (INDIA), I Made BAKTA (Indonesia)

1315 – 1345

CRC - Differences between East and West WU Ming Shiang (Taiwan)

RCC and the Art of Prognostication YE Ding-Wei (China)

Recent improvement in the imaging of pulmonary tumours Jin HUR (South Korea)

Primary prevention: HPV vaccine and it's future TAY Sun Kuie (Singapore)

Principles of communication Cynthia GOH (Singapore)

1345 – 1415

Is (neo)adjuvant therapy necessary in T3 rectal cancer? A surgeon’s view - KOH Poh Koon (Singapore) A medical oncologist’s view - Ian CHAU (UK)

RCC – the Asian anti-angiogenic experience Sun Young RHA (South Korea)

Recent improvement in the radiotherapy of pulmonary tumours FU Xiao Long (China)

Secondary prevention: The role of HPV testing in Asia Pacific Region Efren DOMINGO (Philippines)

Issues surrounding DNR Ednin HAMZAH (Malaysia)

1415 – 1445

Systemic treatment of CRC Ian CHAU (UK)

Systemic management of non-clear renal cell cancer TAY Miah Hiang (Singapore)

Novel EGFR-TKIs Pasi JANNE (USA)

Tertiary prevention: New trends in radiotherapy for cervical cancer Wui-Jin KOH (USA)

Panel discussion: Talking about DNR Stein KAASA (Norway), Ednin HAMZAH (Malaysia), Cynthia GOH (Singapore)

1445 – 1500

Q&A

Q&A

Q&A

Q&A

Q&A

1500 – 1530

Tea Break
Exhibition & Networking

Neuro-Oncology (Nusantara 1, Level 2)
Moderator: Renindra Ananda AMAN (Indonesia)

Skin Cancer (Nusantara 1, Level 2)
Moderator: Bruce MANN (Australia)

1530 – 1600

Genetic basis of glioma and potential for personalised medicine
Michael WELLER (Switzerland)
TBA

Molecular vulnerabilities of melanoma
Richard KEFFORD, Australia

1600 – 1630

New treatment regimens in the pipeline: an overview of current trials in treatment of glioblastoma
Wolfgang WICK (Germany)

Treatment of melanoma: state of the art

1630 – 1645

Q&A

Q&A

End of AOS 2010